+1.224.938.9523

HUMAN AMYLOID IMAGING CONFERENCE

January 15-17, 2020
Miami, Florida

2020 PROGRAM

The event will be held at the Kovens Conference Center at the Florida International University. Access to all sessions, meals, networking receptions will require a conference badge.  

The 2020 Program will be published late November/early December 2019.  


 

HAI’s mobile app provides all the information on the program (with ability to save sessions to your conference schedule), poster presentations, FAQs, logistics, past years’ keynote videocasts, etc.   

Scan the QR code with your mobile phone or access the download through this link: https://my.yapp.us/HAICONF

 

2019 Program
Wednesday, January 16, 2019
10:30 amCheck-in (Grande Promenade Foyer)
11:45Welcome NotesKeith Johnson, Massachusetts General Hospital, Boston, MA, US
12:00 pmSESSION 1: Tracer propertiesCHAIRS:
Roger Gunn, Invicro, Boston, MA, US/Imperial College London, London, UK
Bradley Christian, University of Wisconsin-Madison, Madison, WI, US
12:00Head-to-head in vivo comparison of tau positron emission tomography ligands [18F]Flortaucipir (AV1451) and [18]RO948Michael Schöll, University of Gothenburg, Gothenburg, Sweden
12:15Retrospective comparison of [F-18]MK-6240, [F-18]THK5351 and [F-18]THK-5317 ((S)-THK-5117) in subjects scanned with all three PET tracersTobey Betthauser, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US
12:30Head-to-Head Comparison of neurofibrillary tangles imaging in Alzheimer's diseasePedro Rosa-Neto, McGill University, Montreal, QC, Canada
12:45Assessment of longitudinal change of tau pathology in Alzheimer's disease using [18F]GTP1 (Genentech tau probe 1) PET imagingSandra Sanabria Bohorquez, Genentech, Inc., South San Francisco, CA, US
1:00Evaluation of 18F-PI-2620, a novel selective tau tracer for the assessment of Alzheimer's and non-Alzheimer's tauopathies
Victor Villemagne, Austin Health/The University of Melbourne, Melbourne, Australia
1:15Evidence of differential in vitro and in vivo binding of APN-1607 in progressive supranuclear palsy and Alzheimer's disease
Cristian Salinas, Biogen, Cambridge, MA, US
1:30Discussion Session 1
2:00POSTER SESSION 1 and Coffee Break
3:30SESSION 2: MethodsCHAIRS:
Robert Koeppe, University of Michigan Medical School, Ann Arbor, MI, US
Mark Lubberink, Uppsala University, Uppsala, Sweden
3:30Variability of uptake in potential reference regions for longitudinal flortaucipir-PET analysisJungho Cha, University of California, San Francisco, San Francisco, CA, US
3:45Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer's disease and controlsTessa Timmers, Amsterdam UMC, Amsterdam, The Netherlands
4:00AmyloidIQ demonstrates increased power in longitudinal Amyloid PET studies
Alexander Whittington, Invicro, Boston, MA, US/Imperial College London, London, UK
4:15Evaluation of the Centiloid scale for use in multi-amyloid PET tracer, multi-center trialsJacob Hesterman, Invicro, Boston, MA, US
4:30A comparison of partial volume correction techniques for measuring change in Serial AV-1451 Tau PET SUVR
Christopher Schwarz, Mayo Clinic, Rochester, MN, US
4:45Detecting the earlier stages of amyloid deposition
Tengfei Guo, University of California, Berkeley, CA, US
5:00Discussion Session 2
5:30Keynote LectureRichard Carson, Yale University, New Haven, CT, US
6:00Keynote Discussion
6:15-8:30Welcome Reception
Thursday, January 17, 2019
7:30amCheck-in (Grande Promenade Foyer) and Breakfast (Starlight Ballrooom - 18th Floor)
8:30SESSION 3: Neuropathological validation of amyloid and tau tracersCHAIRS:
Laetitia Lemoine, Karolinska Institute, Stockholm, Sweden
Rik Vandenberghe, KU Leuven, Leuven, Belgium
8:30Neuropathologic correlates of [11C]PiB PET and [11C]altropane dopamine transporter PET in the Lewy body diseasesStephen Gomperts, Massachusetts General Hospital, Boston, MA, US
8:45Postmortem analyses of PiB and Flutemetamol integrated density measures in diffuse and neuritic plaques in Alzheimer's disease
Milos Ikonomovic, University of Pittsburgh, Pittsburgh, PA, US
9:00In vitro characterisation of 3H-MK6240 in human autopsy brain tissue in comparison to the first generation tau PET tracersMona-Lisa Malarte, Karolinska Institute, Stockholm, Sweden
9:15Postmortem binding study of 18F-AV1451 in semantic variant primary progressive aphasiaRik Vandenberghe, University Hospitals Leuven/KU Leuven, Leuven, Belgium
9:30Neuropathologic maturity of neurofibrillary tangles: implications for tau PET imagingMelissa Murray, Mayo Clinic Jacksonville, Jacksonville, FL, US
9:45Discussion Session 3
10:15POSTER SESSION 2A and Coffee Break
11:00SESSION 4: In vivo-postmortem correlates of flortaucipir PETCHAIRS:
Teresa Gomez-Isla, Massachusetts General Hospital, Boston, MA, US
David Wolk, University of Pennsylvania, Philadelphia, PA, US
11:00Pathologic correlations of in vivo [18F]-AV-1451 imaging in autopsy-confirmed Alzheimer's disease, Frontotemporal lobar degeneration with TDP-43 inclusions and control casesCinthya Aguero, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA, US
11:15[18F]Flortaucipir PET and pathology correlations in Alzheimer's disease, non-Alzheimer's tauopathies, and other neurodegenerative diseasesDavid Soleimani-Meigooni, University of California, San Francisco, San Francisco, CA, US
11:30Tau PET imaging correlates with neuropathologyVal Lowe, Mayo Clinic, Rochester, MN, US
11:45Relationships between Flortaucipir PET signal and tau neurofibrillary tangle pathology at autopsyMark Mintun, Avid Radiopharmaceuticals, Philadelphia, PA, US
12:00Discussion Session 4
12:30Keynote Lecture
(This lecture will be recorded)
Michel Goedert, MRC Laboratory of Molecular Biology, Cambridge, UK
1:00Keynote Discussion
1:15Lunch
2:45SESSION 5: Modeling amyloid & tau relationships and spreadCHAIRS:
Elizabeth Mormino, ‎Stanford University, Palo Alto, CA, US
Michel Grothe, German Center for Neurodegenerative Diseases, Rostock, Germany
2:45Data-driven characterization of cross-sectional and longitudinal molecular imaging in aging and Alzheimer's diseaseHugo Botha, Mayo Clinic, Rochester, MN, US
3:00The cortical site of origin and initial spread of medial temporal tauopathy assessed with positron emission tomographyJustin Sanchez, Massachusetts General Hospital, Boston, MA, US
3:15Amyloid and tau pathology are related to functional signal homogeneity and isolation of the hippocampus in cognitively healthy older adultsTheresa Harrison, University of California Berkeley, Berkeley, CA, US
3:30Cross-method identification of earliest regions to display amyloid burdenIsadora Lopes Alves, VU University Medical Center, Amsterdam, The Netherlands
3:45Tau organization precedes Aβ deposition across the brain cortexTharick Pascoal, McGill University, Montreal, QC, Canada
4:00Increased task activation and amyloid independently explain advanced tau pathology in older adultsAnne Maass, German Center for Neurodegenerative Diseases, Magdeburg, Germany
4:15Discussion Session 5
4:45POSTER SESSION 2B and Coffee Break
5:30 - 7:30Networking Reception
Friday, January 18, 2018
7:30amCheck-in (Grande Promenade Foyer) and Breakfast (Starlight Ballrooom - 18th Floor)
8:30SESSION 6: PET and fluid biomarkersCHAIRS:
Oskar Hansson, Lund University, Lund, Sweden
Susan Landau, University of California, Berkeley, Berkeley, CA, US
8:30Longitudinal investigation of concordant vs. discordant amyloid CSF/PET biomarkersArianna Sala, Karolinska Institute, Stockholm, Sweden
8:45CSF and PET tau measures in different stages of Alzheimer's disease
Niklas Mattsson, Lund University, Lund, Sweden
9:00Predicting brain amyloidosis using peripheral blood-based gene expression and early stage neurodegeneration biomarkersApoorva Bharthur Sanjay, Indiana University School of Medicine, Indianapolis, IN, US
9:15Friend or foe? Regional dependent roles of neuroinflammation in Alzheimer's disease pathophysiologyMin Su Kang, McGill Centre for Studying in Aging, Verdun, QC, Canada
9:30Discussion Session 6
10:00POSTER SESSION 3A and Coffee Break
10:45SESSION 7: Multi-modality: cognitively normalCHAIRS:
William Jagust, University of California, Berkeley, Berkeley, CA, US
Tobey Betthauser, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US
10:45Protective effect of physical activity on prospective cognitive decline and longitudinal neurodegeneration in clinically normal older adults with elevated β-amyloid burdenJennifer Rabin, Massachusetts General Hospital, Boston, MA, US
11:00MRI measures of neurodegeneration and vascular injury, but not smyloid status predict cognitive decline in normal individuals followed for more than 9 YearsCharles DeCarli, University of California at Davis, Sacramento, CA, US
11:15Fluorodeoxyglucose and Flortaucipir PET independently predict subsequent cognitive decline in clinically normal adults with elevated amyloidBernard Hanseeuw, Massachusetts General Hospital, Boston, MA, US
11:30MK-6240 and PIB PET are associated with retrospective cognitive trajectories in late-middle aged persons clinically unimpaired at baselineSterling Johnson, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US
11:45Individual variations in sleep architecture are associated with tau PET, cognition, and functional network architecture: preliminary findings from the Harvard Aging Brain StudyJasmeer Chhatwal, Massachusetts General Hospital, Boston, MA, US
12:00Discussion Session 7
12:30Keynote Lecture:
Tau strains and spreading in pure tauopathies and Alzheimer’s disease

(This lecture will be recorded)
John Trojanowski, University of Pennsylvania, Philadelphia, PA, US
1:00Keynote Discussion
1:15Lunch
2:30SESSION 8: Multi-modality: patient populationsCHAIRS:
Ann Cohen, University of Pittsburgh, Pittsburgh, PA, US
Keith Johnson, Massachusetts General Hospital, Boston, MA, US
2:30Tau imaging with [18F]Flortaucipir predicts the severity and the topography of subsequent cortical atrophy in patients with Alzheimer's diseaseRenaud La Joie, University of California, San Francisco, San Francisco, CA, USA
2:45Epidemic spreading of tau through human functional brain connectionsJacob Vogel, Montreal Neurological Institute, McGill University, Montreal, QC, Canada
3:00Spatial extent and topographical relationships between pathology accumulation and neurodegeneration in Alzheimer's diseaseLeonardo Iaccarino, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA, US
3:15Functional connectivity associated with tau levels in aging, Alzheimer's, and small-vessel diseaseNicolai Franzmeier, Ludwig-Maximilians-Universität LMU, Munich, Germany
3:30Associations between longitudinal Aβ and cross-sectional tau in adults with Down syndrome
Dana Tudorascu, University of Pittsburgh, Pittsburgh, PA, US
3:45Discussion Session 8
4:15POSTER SESSION 3B and Coffee Break
5:00Awards Ceremony
5:05SESSION 9: Clinical applicationsCHAIRS:
Pedro Rosa-Neto, McGill University, Montreal, QC, Canada
Gil Rabinovici, University of California, San Francisco, CA, US
5:05Tau PET imaging with 18F-PI2620 in aging and neurodegenerative diseasesElizabeth Mormino, Stanford University, Palo Alto, CA, US
5:20In vivo distribution pattern of 18F-PM-PBB3 (18F-APN-1607) and its relationship with clinical features in diverse 4-repeat tauopathiesHitoshi Shimada, National Institute of Radiological Sciences/National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
5:35
Tau imaging with 18F-MK6240 in Alzheimer's disease and in past traumatic brain injuryChristopher Rowe, Austin Health/The University of Melbourne, Melbourne, Australia
5:50[18F]-AV-1451 binding profile in early and late-onset Alzheimer's disease and suspected non-Alzheimer pathophysiologyEddie Stage, Indiana University School of Medicine, Indianapolis, IN, US
6:05Towards a topographic imaging biomarker of TDP-43 pathology in amnestic dementia: patient stratification based on FDG-PET patterns in autopsy-confirmed casesMichel Grothe, German Center for Neurodegenerative Diseases, Rostock, Germany
6:20Discussion Session 9

The 18th Mild Cognitive Impairment Symposium and Special Topic Workshop (CME/CE accredited) will follow immediately on January 18-19, 2020 at the same venue. 

MCI website

2020 KEYNOTE LECTURES


ALAN EVANS, PhD

Dr. Alan Evans is a James McGill Professor of Neurology and Neurosurgery, Psychiatry and Biomedical Engineering at McGill University since 2009, and a researcher in the McConnell Brain Imaging Centre (BIC) of the Montreal Neurological Institute.

He is co-director of the Ludmer Centre for Neuroinformatics and Mental Health and is Principal Investigator of CBRAIN, a pan-Canadian project to integrate Canadian brain research with the Compute Canada high-performance computing grid. He is the sole Canadian participant in the $1.1 billion European Human Brain Project, and is a co-principal investigator of the Big Brain project. He is Scientific Director of McGill’s $84 million CFREF project, “Healthy Brains for Healthy Lives.”

Dr. Evans heads the Data Coordinating Center for a large NIH multi-centre MRI study of normal pediatric development. This provides a web-accessible reference database of neuroanatomical and behavioral maturation.  Dr. Evans was principal investigator in the Montreal Consortium for Brain Imaging Research (MCBIR), which was founded in 2000 with a $35 million award from the Canada Foundation for Innovation.  He was a co-founder of the International Consortium for Brain Mapping (ICBM), a multinational effort funded by the U.S. Human Brain Project to create a computational atlas of the adult human brain. He was one of the founders of the Organization for Human Brain Mapping (OHBM), serving in numerous positions on the OHBM Council since 1995.

Dr. Evans’ research interests include cognitive neuroimaging, neuroanatomical variability, and image-processing methodologies for PET and MRI. He pioneered the technique of multi-modal 3D brain imaging with PET and MRI, which provides detailed 3D images of brain anatomy.

As BIC Coordinator from 1992 to 2000, Dr. Evans fostered the development of brain “activation” studies in which specific brain regions show subtle changes in blood flow in response to cognitive and sensorimotor stimuli. This so-called brain-mapping technique is widely used to map human brain functions. Dr. Evans extended these techniques to large-scale studies of brain anatomy.  This work has spun off a new company, Biospective Inc., which performs fully automated analysis of neuroimaging databases collected as part of pharmaceutical clinical trials.

Dr. Evans has published over 550 peer-reviewed papers, and is a member of numerous international advisory boards, review panels and research collaborations. He was acknowledged as a Thompson-Reuters Highly Cited Scientist for 2014 and 2015 (top 1% in Neuroscience and Behaviour).

JULIE SCHNEIDER, MD, MS

Dr. Julie A. Schneider is the The Deborah R. And Edgar D. Jannotta Presidential Professor of Pathology (Neuropathology) and Neurological Sciences, and Associate Director at the Rush Alzheimer’s Disease Center, at Rush University Medical Center.  She completed her Neurology residency at the University of Chicago and Neuropathology fellowship at Emory University in Atlanta and is board certified in both specialties.

Dr. Schneider is also certified in Geriatric Neurology, and has a Master’s Degree in Clinical Research with a focus in Epidemiology.  She is the Neuropathology Core Leader of the Rush Alzheimer’s Disease Center and the senior neuropathologist for multiple studies including the Religious Orders Study, Rush Memory and Aging Project, and Rush Minority Aging Research Study, Rush Latino Core, and NCRAD (National Cell Repository for Alzheimer’s disease).  

Dr. Schneider has provided peer review for over 25 journals; has been invited to multiple journal editorial boards; and has provided numerous grant peer reviews for the National Institutes of Health, Alzheimer’s Association, and other agencies. She has served on numerous scientific and external national and international advisory boards for academia and industry; and has presented findings from her research both nationally and internationally.  

Dr. Schneider has extensive experience with clinical-pathologic epidemiologic studies of aging and dementia and has over 300 peer-reviewed publications and 4 book chapters.  She also has extensive experience collaborating with researchers, participating in multicenter grants and initiatives, and partnerships with industry to advance science.  

The foundation of Dr. Schneider’s research is the exploration of pathologic factors in the clinical expression of cognitive decline in aging, with a focus on vascular, TDP-43, hippocampal sclerosis and mixed pathologies in Alzheimer’s and related dementias.  

Dr. Schneider has over 300 peer-reviewed publications and an H-factor of 104.  Her current research leverages neuropathology to advance understanding of risk, methods for diagnosis, and biomarker development for vascular, TDP, and mixed pathologies.    

LI-HUEI TSAI, PhD

Dr. Li-Huei Tsai is a leader in understanding the molecular pathophysiology of neurological disorders affecting cognition. Her work has brought new mechanisms for learning, memory and neurodegeneration to light and suggests new paths for combating age-related memory loss.

Landmark discoveries include pinpointing major genetic risk for Alzheimer’s disease to immune genes, identifying chromatin-modifiers and kinases that regulate brain flexibility and can be targeted to improve cognition in Alzheimer’s disease, and discovering that genomic integrity is critical for neuronal protection during both aging and neurodegenerative disease.

In 2019, Dr. Tsai won the Hans Wigzell Prize in Medicine for 2018 for her innovative research in trying to understand the etiology and possible treatment of Alzheimer’s disease.  She is a recipient of the Young Investigator Award, Metropolitan Life Foundation, Outstanding Contributor Award of the Alzheimer Research Forum, the NIH Cantoni Lecture Award and the Glenn Award For Research in Biological Mechanisms of Aging.

Dr. Tsai is Director of the The Picower Institute for Learning and Memory, Picower Profess or Neuroscience and Senior Associate Member, Broad Institute.

She is a Fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences, the Neurodegeneration Consortium and Taiwan’s Academia Sinica.

Dr. Tsai has authored and co-authored over 130 peer-reviewed articles published in Nature, Cell, Neuron, Molecular Psychiatry, The Journal of Neuroscience, Nature Neuroscience, and the Proceedings of the National Academy of Sciences.  Her research has been featured in National Geographic and the Boston Globe.